Ali Buwaider, Mathan Kananathan, Sara Tabari, Sofia Hylin, Bodo Lippitz, Elfar Úlfarsson, Petter Förander, Michael Gubanski, Tiit Mathiesen, Alexander Fletcher-Sandersjöö, Jiri Bartek
{"title":"Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years.","authors":"Ali Buwaider, Mathan Kananathan, Sara Tabari, Sofia Hylin, Bodo Lippitz, Elfar Úlfarsson, Petter Förander, Michael Gubanski, Tiit Mathiesen, Alexander Fletcher-Sandersjöö, Jiri Bartek","doi":"10.1227/neu.0000000000003394","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort.</p><p><strong>Methods: </strong>All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed.</p><p><strong>Results: </strong>A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival.</p><p><strong>Conclusion: </strong>GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003394","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort.
Methods: All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed.
Results: A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival.
Conclusion: GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.
期刊介绍:
Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery.
Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.